Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.3400 +0.0154 (+4.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroBiologics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces 2025 Annual Meeting of Stockholders
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to also present at the BIO CEO & Investor Conference 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
From D. Boral Capital
Via GlobeNewswire
News headline image
FibroBiologics Announces $25 Million Financing
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Engages Southern Star Research as CRO in Australia
Southern Star Research will provide CRO services for FibroBiologics in Australia 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
From Fibrobiologics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.